Cambridge Investment Research Advisors Inc. cut its holdings in Intrexon Corporation (NYSE:XON) by 5.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 64,546 shares of the biotechnology company’s stock after selling 3,444 shares during the period. Cambridge Investment Research Advisors Inc. owned 0.05% of Intrexon Corporation worth $1,227,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in XON. Vanguard Group Inc. raised its position in Intrexon Corporation by 3.4% in the second quarter. Vanguard Group Inc. now owns 4,433,879 shares of the biotechnology company’s stock valued at $106,811,000 after purchasing an additional 147,517 shares during the period. First Trust Advisors LP raised its position in Intrexon Corporation by 3.4% in the third quarter. First Trust Advisors LP now owns 1,588,779 shares of the biotechnology company’s stock valued at $30,203,000 after purchasing an additional 51,691 shares during the period. Peregrine Capital Management LLC raised its position in Intrexon Corporation by 25.3% in the third quarter. Peregrine Capital Management LLC now owns 583,328 shares of the biotechnology company’s stock valued at $11,089,000 after purchasing an additional 117,605 shares during the period. Geode Capital Management LLC raised its position in Intrexon Corporation by 3.5% in the first quarter. Geode Capital Management LLC now owns 429,532 shares of the biotechnology company’s stock valued at $8,513,000 after purchasing an additional 14,674 shares during the period. Finally, Northern Trust Corp raised its position in Intrexon Corporation by 2.4% in the second quarter. Northern Trust Corp now owns 322,110 shares of the biotechnology company’s stock valued at $7,760,000 after purchasing an additional 7,589 shares during the period. Hedge funds and other institutional investors own 77.17% of the company’s stock.

A number of analysts have issued reports on XON shares. Zacks Investment Research lowered Intrexon Corporation from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. Griffin Securities reissued a “buy” rating and issued a $55.00 target price on shares of Intrexon Corporation in a research report on Friday, October 6th. Northland Securities reissued a “buy” rating and issued a $21.00 target price on shares of Intrexon Corporation in a research report on Friday, November 10th. JMP Securities reissued an “outperform” rating and issued a $42.00 target price on shares of Intrexon Corporation in a research report on Thursday, October 5th. Finally, BidaskClub lowered Intrexon Corporation from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 22nd. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $38.50.

Shares of Intrexon Corporation (XON) opened at $12.37 on Wednesday. Intrexon Corporation has a 12-month low of $10.26 and a 12-month high of $31.68. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.85 and a current ratio of 2.05.

TRADEMARK VIOLATION WARNING: This piece was originally published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.watchlistnews.com/intrexon-corporation-xon-position-reduced-by-cambridge-investment-research-advisors-inc/1719512.html.

Intrexon Corporation Profile

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Want to see what other hedge funds are holding XON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intrexon Corporation (NYSE:XON).

Institutional Ownership by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.